Evotec and Boehringer Ingelheim Venture Fund returned in a $25.9m round for the autoimmune disease drug developer having first invested three years ago.
Topas Therapeutics, a Germany-based developer of treatments for autoimmune diseases, completed a €22m ($25.9m) series B round yesterday backed by pharmaceutical company Evotec and Boehringer Ingelheim.
The round was co-led by Vesalius BioCapital III and BioMedPartners and included EMBL Ventures, the investment arm of European Molecular Biology Laboratory, as well as Epidarex Capital and Gimv, while Boehringer Ingelheim invested through Boehringer Ingelheim Venture Fund (BIVF).
Founded in 2003, Topas is working on therapies for autoimmune diseases. Its lead asset, TPM203,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
